Browse News
Filter News
Found 110 articles
-
Erasca Announces $45 Million Oversubscribed Private Placement Financing
3/28/2024
Erasca, Inc. announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 21,844,660 shares of its common stock in an oversubscribed private placement at a price of $2.06 per share.
-
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
3/27/2024
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2023.
-
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
2/14/2024
Erasca, Inc. today announced two clinical trial collaboration and supply agreements (CTCSAs) with Novartis (NYSE: NVS) for the MEK inhibitor trametinib (MEKINIST®).
-
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2/1/2024
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 6th Annual Guggenheim Biotechnology Conference being held at the St. Regis in New York, New York.
-
2seventy bio Announces New Strategic Path Forward
1/30/2024
2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T therapy for multiple myeloma.
-
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Erasca, Inc. today announced its participation in the 42nd annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA.
-
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
12/11/2023
Erasca, Inc. (Nasdaq: ERAS) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to naporafenib in combination with trametinib (MEKINIST®) for the treatment of adult patients with unresectable or metastatic melanoma who have progressed on, or are intolerant to, an anti‑programmed death-1 (ligand 1) (PD‑(L)1)-based regimen, and whose tumors contain an NRAS mutation (NRASm).
-
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
11/28/2023
Erasca, Inc. announced program updates for pan-RAF inhibitor naporafenib and central nervous system -penetrant EGFR inhibitor ERAS-801, as well as a strategic program prioritization that extends its projected cash runway from H2 2025 to H1 2026.
-
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
11/9/2023
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the fiscal quarter ended September 30, 2023, and provided business updates.
-
Erasca to Present at Upcoming Investor Conferences in November 2023
11/8/2023
Erasca, Inc. announced that management will participate in the following investor conferences in November 2023.
-
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
11/1/2023
Eterna Therapeutics Inc. today announced the appointment of James Bristol, Ph.D., to its Board of Directors.
-
Erasca to Present at the Cantor Global Healthcare Conference
9/19/2023
Erasca, Inc. today announced that management will participate in a fireside chat on Tuesday, September 26, 2023, at 8:10 am Eastern Time at the Cantor Global Healthcare Conference, which is being held at the InterContinental New York Barclay in New York, New York.
-
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
9/5/2023
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in a fireside chat on Tuesday, September 12, 2023, at 5:30 pm Eastern Time at the Morgan Stanley 21st Annual Global Healthcare Conference.
-
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
8/29/2023
Erasca, Inc. (Nasdaq: ERAS) today announced dosing of the first patient in the SEACRAFT-1 Phase 1b trial evaluating pan-RAF inhibitor naporafenib in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.
-
Erasca Reports Second Quarter 2023 Financial Results and Business Updates
8/10/2023
Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported financial results for the fiscal quarter ended June 30, 2023, and provided business updates.
-
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/8/2023
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
-
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma
6/22/2023
Erasca, Inc. (Nasdaq: ERAS) today announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ERAS-801 for the treatment of malignant glioma, which includes glioblastoma (GBM).
-
Sientra Announces Appointment of Alexander W. Casdin to Board of Directors
6/20/2023
Sientra, Inc. announced the appointment of Alexander W. Casdin to the Company’s Board of Directors, effective June 15, 2023.
-
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline
6/5/2023
Erasca, Inc. (Nasdaq: ERAS) today announced promising preliminary Phase 1b data for ERK inhibitor ERAS-007 in patients with metastatic BRAF V600E-mutated (BRAFm) colorectal cancer (CRC) and provided a portfolio update.
-
Erasca to Present at Upcoming June 2023 Investor Conferences
6/1/2023
Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced that management will present at the investor conferences listed below.